It will be interesting to compare outcomes with 1L platinum-pemetrexed-PD-(L)1 inhibitor (on the basis of the IND.227 trial results26) with 1L ipi-nivo in patients with epithelioid MPM, particularly in the presence of high tumor burden or systemic inflammatory markers to better understand whether the addition of chemotherapy to immunotherapy might mitigate the negative impact of elevated inflammatory markers on immunotherapy outcomes. This evidence concerns the gene CD274 and neoplasm.